Interactions between microbiome and lungs: Paving new paths for microbiome based bio-engineered drug delivery systems in chronic respiratory diseases. (1st September 2019)

• Record Type: Journal Article
• Authors: Chellappan, Dinesh Kumar; Sze Ning, Quinnie Ling; Su Min, Sandra Khoo; Bin, Saw Yan; Chern, Pang Jia; Shi, Tan Pei; Ee Mei, Sylvia Wong; Yee, Tan Hui; Qi, Ong Jing; Thangavelu, Lakshmi; Rajeshkumar, S.; Negi, Poonam; Chellian, Jestin; Wadhwa, Ridhima; Gupta, Gaurav; Collet, Trudi; Hansbro, Philip M.; Dua, Kamal
• Is Part Of: Chemico-biological interactions. Volume 310(2019)
• Publication Date: 2019-09-01
• Subjects: Microbiome -- Drug delivery -- Respiratory disease -- Gut-lung axis -- Engineered microbiome-derived therapeutics; Biochemistry -- Periodicals; Toxicological chemistry -- Periodicals; Biochemistry -- Periodicals; Biologie moléculaire -- Périodiques; Biochimie -- Périodiques; Toxicologie biochimique -- Périodiques; 572
• DOI: 10.1016/j.cbi.2019.108732
• Languages: English
• ISSNs: 0009-2797

Abstract

Abstract: Background: The human body is a home to thousands of microbiotas. It is defined as a community of symbiotic, commensal and pathogenic microorganisms that have existed in all exposed sites of the body, which have co-evolved with diet, lifestyle, genetic factors and immune factors. Human microbiotas have been studied for years on their effects with relation to health and diseases. Methods: Relevant published studies, literature and reports were searched from accessible electronic databases and related institutional databases. We used keywords, viz ; microbiome, microbiota, microbiome drug delivery and respiratory disease. Selected articles were carefully read through, clustered, segregated into subtopics and reviewed. Findings: The traditional belief of sterile lungs was challenged by the emergence of culture-independent molecular techniques and the recently introduced invasive broncho-alveolar lavage (BAL) sampling method. The constitution of a lung microbiome mainly depends on three main ecological factors, which include; firstly, the immigration of microbes into airways, secondly, the removal of microbes from airways and lastly, the regional growth conditions. In healthy conditions, the microbial communities that co-exist in our lungs can build significant pulmonary immunity and could act as a barrier against diseases, whereas, in an adverse way, microbiomes may interact with other pathogenic bacteriomes and viromes, acting as a cofactor in inflammation and host immune responses, which may lead to the progression of a disease. Thus, the use of microbiota as a target, and as a drug delivery system in the possible modification of a disease state, has started to gain massive attention in recent years. Microbiota, owing to its unique characteristics, could serve as a potential drug delivery system, that could be bioengineered to suit the interest. The engineered microbiome-derived therapeutics can be delivered through BC, bacteriophage, bacteria-derived lipid vesicles and microbe-derived extracellular vesicles. This review highlights the relationships between microbiota and different types of respiratory diseases, the importance of microbiota towards human health and diseases, including the role of novel microbiome drug delivery systems in targeting various respiratory diseases. Highlights: Microbiome-based therapeutics deeply impact pharmaceutical and medical fields. Engineered bacteriophage has potential antibiotic adjuvant activity. Crosstalk between lung and gut microbiota influences immune response. These bio-systems has potential to improve patient compliance and drug profile.